Emory Children's Center
Led by Andrew Muir, MD, the TrialNet team at Emory is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Note: As a TrialNet affiliate, Emory is regionally overseen by University of Florida. If you reach out to TrialNet, you may be contacted by staff from either institution.
Our Team
Andrew Muir, MD
Eric Felner, MD
Kristina Cossen, MD
Xiaomiao Lanpidhainy, RN
Lynette Gonzalez
Tejiri Ededey
Linton Cuff
Research Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet tested a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it could delay or prevent type 1 diabetes (T1D) in people ages 6 to 34 who had a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk was defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
